Waiv Raises $33M to Revolutionize Cancer Testing with AI

Waiv, a Paris-based medical testing startup spun out of biotech unicorn Owkin, has raised $33 million in a new funding round to advance its AI-powered approach to cancer diagnostics and drug discovery. The company aims to revolutionize cancer screening by enabling more precise testing through artificial intelligence.

The funding comes as part of a broader trend of AI-driven healthcare innovations, with Waiv joining other startups leveraging machine learning to improve medical outcomes. By spinning out from Owkin, which has established itself as a leader in AI diagnostics, Waiv benefits from existing expertise while focusing specifically on cancer testing applications.

Waiv's technology represents a significant advancement in medical diagnostics, using AI to analyze complex biological data and identify cancer markers with greater accuracy than traditional methods. This approach could lead to earlier detection and more personalized treatment plans for patients.

For more information about Waiv's technology and mission, visit their official website.